glp-1 ras Frontiers GLP-1 receptor agonists (GLP-1RAs): cardiovascular

Add psoriatic arthritis | 47 comments on LinkedIn

The FDA also raised concerns about contamination, incorrect dosages, unapproved or harmful ingredients, and counterfeit components in compounded GLP-1s

In our newly released white paper, From Managing Illness to Building Health, we outline why fragmented, condition-specific approaches are no longer aligned with clinical science or financial outcomes and what a more integrated, prevention-focused model looks like in practice

p=0.030) and 25% higher at 12 months (95% CI: 2 to 59

While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron

It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.